# Synthesis and Evaluation of Antiviral Activity of L-Acosamine and L-Ristosamine Nucleosides of Furanose Configuration

Jesper Lau,<sup>a</sup> Erik B. Pedersen<sup>a</sup> and Carsten M. Nielsen<sup>b</sup>

<sup>a</sup> Department of Chemistry, Odense University, DK-5230 Odense M, Denmark and <sup>b</sup> Retrovirus Laboratory, Enterovirus Department, Statens Seruminstitut, Amager Boulevard 80, DK-2300 Copenhagen, Denmark

Lau, J., Pedersen, E. B. and Nielsen, C. M., 1991. Synthesis and Evaluation of Antiviral Activity of L-Acosamine and L-Ristosamine Nucleosides of Furanose Configuration. – Acta Chem. Scand. 45: 616–620.

Mercuric-catalyzed hydrolysis of acetylated L-rhamnal 1 gives an  $\alpha,\beta$ -unsaturated aldehyde 2. 1,4-Addition of DBU-phthalimide salt with concomitant acetyl shift resulted in L-ribo and L-arabino isomers of 5-O-acetyl-2,3,6-trideoxy-3-phthalimido-hexofuranose 3 and 4. After acetylation at the anomeric center, coupling with silylated thymine resulted in three new nucleosides, with L-acosamine and L-ristosamine of furanose configuration as the carbohydrate moiety. The target compounds have been evaluated for their antiviral activity against HIV and HSV-1.

The 3-amino-2,3,6-trideoxyhexoses, L-daunosamine (lyxo), L-acosamine (arabino), L-ristosamine (ribo) and 3-epi-daunosamine (xylo) are distributed in nature as the glycosidic moiety of several important antibiotics, which, together with synthetic analogs, exhibit impressive anticancer activity. 1-3 In addition, synthetic 3'-amino-2',3'-dideoxy nucleosides are described as biologically active against murine sarcoma virus 180 cells and murine L1210 cells in vitro<sup>4-7</sup> and show antiviral activity against adenovirus<sup>8</sup> and HSV.<sup>9</sup> Furthermore, 3'-amino-2',3'-dideoxy nucleosides are reported to have moderate activity against Moloney murine leukemia (M-MULV) which is caused by a mammalian T-lymphotropic retrovirus, 10 and to inhibit the enzyme reverse transcriptase in vitro, 11 although the activities against HIV infected human cells are reported to be rather limited.12

In connection with our investigation of new 3'-amino-2'-3'-dideoxy nucleosides, <sup>13-15</sup> we present a new method for the preparation of protected L-acosamine 6 and L-ristosamine 5 possessing the furanose configuration. These two new carbohydrates are used for the preparation of three new thymine derivatives 11, 12 and 13 in order to evaluate the antiviral activities of these compounds. The synthesis of new 3'-substituted 2',3'-dideoxy nucleosides is of increasing importance in the quest to combat AIDS. <sup>12</sup>

## Chemistry

The L-ribo and L-arabino isomers of 5-O-acetyl-2,3,6-tride-oxy-3-phthalimidohexofuranose **3** and **4** were obtained in two steps from commercially available acetylated L-rhamnal **1**. Mercuric-catalyzed hydrolysis of L-rhamnal gave the  $\alpha,\beta$ -unsaturated aldehyde **2**<sup>17</sup> in 91 % yield. Subsequently, 1,4-addition of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) phthalimide salt together with a concomitant acetyl

Scheme 1.

shift from 4-O to 5-O of the aldehyde resulted in ring closure to give 3 and 4 in 30 and 21 % yield, respectively, after purification. Finally, acetylation of 3 and 4 gave the desired carbohydrates 5 and 6 suitable for synthesis of a new class of amino nucleosides.

Application of the reported<sup>18,19</sup> procedure for nucleoside synthesis using trimethylsilyl trifluoromethanesulfonate (TMS-triflate) as a Lewis acid, resulted in the protected 3'-phthalimido nucleosides 8, 9 and 10. When the *ribo* isomer 5 was used as the substrate in the synthesis of nucleosides, a 1:1 anomeric mixture of 8 and 9 was obtained which could be separated by means of preparative

$$\mathbf{5} + \mathbf{Me_{3}SiO} \mathbf{7}$$

$$\mathbf{7}$$

$$\mathbf{11}$$

$$\mathbf{AcO} \mathbf{NH}$$

$$\mathbf{AcO} \mathbf{NH}$$

$$\mathbf{11}$$

$$\mathbf{AcO} \mathbf{NH}$$

$$\mathbf{11}$$

$$\mathbf{AcO} \mathbf{NH}$$

$$\mathbf{12}$$

$$\mathbf{12}$$

$$\mathbf{10}$$

$$\mathbf{13}$$

$$\mathbf{10}$$

$$\mathbf{13}$$

$$\mathbf{11}$$

$$\mathbf{13}$$

$$\mathbf{11}$$

$$\mathbf{13}$$

$$\mathbf{11}$$

$$\mathbf{11}$$

$$\mathbf{12}$$

$$\mathbf{10}$$

$$\mathbf{12}$$

$$\mathbf{13}$$

Scheme 2.

HPLC. On the other hand, only one anomer 10 was obtained when the *arabino* isomer 6 was used as the substrate. The rather bulky  $\beta$ -substituents on C-3 and C-4 may explain the steric hindrance offered by the  $\beta$ -face of the furanose ring towards nucleophilic attack by the thymine base. Deprotection of 8, 9 and 10 by treatment with methylamine in absolute ethanol finally gave the amino nucleosides 11, 12 and 13 after chromatographic purification.

The configuration assignment of the carbohydrate substrates 5 and 6 as well as the nucleosides was made by comparison with similar compounds. 13-15 In particular, the β-D-ribo and α-D-arabino isomers of 1,5,6-tri-O-acetyl-2,3dideoxy-3-phthalimodohexofuranoses<sup>15,20</sup> display very similar <sup>1</sup>H NMR shifts for the furanose ring protons when compared with 5 and 6, respectively. Thus, in the dideoxy carbohydrates, 1-H of the  $\beta$ -D-ribo isomer is a doublet (5.0 Hz) at 6.52 ppm, very similar to 1-H of compound 5 which shows a doublet (4.9 Hz) at 6.48 ppm. On the other hand, the α-D-arabino isomer of the dideoxy carbohydrate is a double doublet (6.0 Hz and 3.5 Hz) at 6.60 ppm which is comparable to 1-H of compound 6 where a double doublet (6.0 Hz and 2.8 H) at 6.72 ppm is found. The <sup>1</sup>H NMR spectra of the nucleosides 8-13 are likewise very similar to the corresponding isomers from the 2,3-dideoxy nucleosides.15

## **Biological activity**

The compounds 11 and 12 showed 42 and 54 % protection, respectively, at 100  $\mu$ M against Herpes Simplex Virus type (HSV-1), strain McIntyre, when propagated in a continuous cell line from rabbit cornea (SIRL) which was maintained in Eagle's MEM containing 1 % fetal calf serum and

antibiotics. No toxicity against the cells was observed at  $100 \, \mu M$ . The compounds 8–13 were devoid of any activity against HVI-1 (strain HTLV-IIIB) in MT-4 cells.

#### **Experimental**

<sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AC 250 FT NMR spectrometer. Microanalyses were carried out by NOVO Microanalytical Laboratory A/S, Novo Allé, DK-2880 Bagsværd. EI mass spectra were recorded on a Varian MAT 311A spectrometer.

(E)-4-O-Acetyl-2,3,6-trideoxy-aldehydo-L-erythro-hex-2enose (2). Peracetylated L-rhamnal 1 (15.0 g, 70.0 mmol) was dissolved in acetone (150 ml). Mercuric sulfate (1.45 g, 4.8 mmol) and 5 mM sulfuric acid (250 ml) was immediately added. After 5 h at room temperature, analytical silica TLC showed a single spot (diethyl ether-hexane 4:1). The reaction mixture was extracted with chloroform  $(10\times50 \text{ ml})$  and the combined organic phases washed with a saturated solution of sodium hydrogenearbonate (2×50 ml) and water (50 ml). After being dried over anhydrous magnesium sulfate, the solution was concentrated to a clear oil at reduced pressure. NMR spectroscopy showed this crude product to be sufficiently pure for the next reaction. Yield 11.2 g (91 %) of 2. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.24 (d, 3 H, J = 6.5 Hz, 6-H), 2.16 (s, 3 H, OAc), 2.88 (br s, 1 H, OH), 4.02-4.08 (m, 1 H, 5-H), 5.44 (td, 1 H, J = 5.3, 1.4 Hz, 4-H), 6.25 (ddd, 1 H, J = 15.9, 7.7, 1.4 Hz, 2-H), 6.87 (dd, 1 H, J = 15.9, 5.3 Hz, 3-H, 9.57 (d, 1 H, J = 7.7 Hz, 1-H).<sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  18.02 (C-6), 20.45 (OAc), 68.15 (C-5), 75.89 (C-4), 132.77 (C-2), 150.40 (C-3), 192.99 (C-1).

5-O-Acetyl-2,3,6-trideoxy-3-phthalimido-L-ribo-hexofuranose (3) and 5-O-Acetyl-2,3,6-trideoxy-3-phthalimido-Larabino-hexofuranose (4). A solution of  $\alpha,\beta$ -unsaturated aldehyde 2 (11.0 g, 63.9 mmol) in dichloromethane (50 ml) was added dropwise, over a period of 1 h, to a cold (0°C) solution of DBU-phthalimide salt<sup>20</sup> (15.0 g, 51.0 mmol) dissolved in dichloromethane (200 ml). After additional 2 h at 0 °C the reaction mixture was washed with ice-cold 1 M sulfuric acid (3×100 ml) and water (100 ml). After being dried over anhydrous magnesium sulfate the solution was concentrated to a yellow oil (14.4 g) at reduced pressure. The oil was further dried on an oil pump after which addition of dry diethyl ether (200 ml) gave a precipitate of 4 after the solution had been allowed to stand for 3 days at -18 °C. Yield 3.40 g (21 %), m.p. 117–119 °C. Pure  $\alpha$ isomer of 4 could be isolated by recrystallization from abs. ethanol.

α-isomer of 4: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.28 (d, 3 H, J = 6.3 Hz, 6-H), 1.84 (s, 3 H, OAc), 2.36 (ddd, 1 H, J = 14.3, 9.2, 2.8 Hz, 2α-H), 2.76 (ddd, 1 H, J = 14.3, 5.8, 2.3 Hz, 2β-H), 3.08 (br s, 1 H, OH), 4.31 (dd, 1 H, J = 8.6, 5.3 Hz, 4-H), 4.83 (dq, 1 H, J = 8.6, 6.3 Hz, 5-H), 5.08 (ddd, 1 H, J = 9.2, 5.3, 2.3 Hz, 3-H), 6.02 (dd, 1 H, J = 5.8, 2.8 Hz, 1-H), 7.27–7.86 (m, 4 H, phth). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 17.06 (C-6), 20.79 (OAc), 38.33 (C-2), 50.89 (C-3), 68.08 (C-5), 81.40 (C-4), 98.52 (C-1), 123.09 (C'-4), 131.49 (C'-3a), 134.06 (C'-5), 168.04 (C'-2), 169.82 (OAc). Anal. (C<sub>16</sub>H<sub>17</sub>NO<sub>6</sub>): C, H, N.

The mother liquid was purified by flash chromatography (Merck silica 230–400 mesh,  $3\times45$  cm, diethyl ether-hexane 7:3) to give 6.11 g (30%) of almost pure *ribo* isomer 3.

 $1,5\text{-}Di\text{-}O\text{-}acetyl\text{-}2,3,6\text{-}trideoxy\text{-}3\text{-}phthalimido\text{-}\beta\text{-}L\text{-}ribo\text{-}hex\text{-}}$ ofuranose (5). Compound 3 (6.0 g, 18.8 mmol) was acetylated with acetic anhydride (3.8 g, 37.2 mmol) and pyridine (3.0 g, 37.9 mmol) in dry dichloromethane (50 ml). After 3 h at 20 °C the reaction mixture was washed with ice-cold 1 M hydrochloric acid (3×15 ml) and water (15 ml). After being dried over anhydrous magnesium sulfate, the solution was evaporated to a white solid at reduced pressure. Flash chromatographic purification (Merck silica 230-400 mesh, dichloromethane-methanol 97:3) gave pure 5. Yield 4.8 g (71 %), m.p. 108–109 °C. ¹H NMR (CDCl<sub>3</sub>): δ 1.28 (d, 3 H, J = 6.3 Hz, 6-H), 1.96 (s, 3 H, OAc), 2.10 (s, 3 H, OAc)OAc), 2.26 (dd, 1 H, J = 13.1, 8.3 Hz, 2 $\beta$ -H), 3.05 (ddd, 1 H, J = 13.1, 8.0, 4.9 Hz,  $2\alpha$ -H), 4.43 (t, 1 H, J = 7.0 Hz, 4-H), 4.88-5.02 (m, 2 H, 3-H; 5-H), 6.48 (d, 1 H, J = 4.9Hz, 1-H), 7.72–7.89 (m, 4 H, phth).  ${}^{13}$ C NMR (CDCl<sub>3</sub>):  $\delta$ 16.36 (C-6), 20.81 (OAc), 21.02 (OAc), 34.80 (C-2), 50.02 (C-3), 71.71 (C-5), 82.39 (C-4), 97.87 (C-1), 123.19 (C'-4), 131.32 (C'-3a), 134.14 (C'-5), 167.70 (C'-2), 169.52 (OAc). Anal. (C<sub>18</sub>H<sub>19</sub>NO<sub>7</sub>): C, H, N.

1,5-Di-O-acetyl-2,3,6-trideoxy-3-phthalimido-α-L-arabino-hexofuranose (6). Compound 4 (2.5 g, 7.8 mmol) was acetylated with acetic anhydride (0.8 g, 7.8 mmol) and pyridine (0.9 g, 11.4 mmol) in dichloromethane (50 ml) to-

gether with catalytic amount of 4-dimethylaminopyridine (20 mg). After 3 h at 20 °C the reaction mixture was washed with ice-cold 1 M sulfuric acid (3×15 ml) and water (15 ml). After being dried over magnesium sulfate the organic phase was concentrated to a solid at reduced pressure. Flash chromatographic purification (Merck silica 230-400 mesh, 3×40 cm, dichloromethane-methanol 97:3) gave pure 6 as a white solid. Yield 2.2 g (78%), m.p. 154-156 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  1.30 (d, 3 H, J = 6.2 Hz, 6-H), 1.84 (s, 3 H, OAc), 2.10 (s, 3 H, OAc), 2.46 (ddd, 1 H, J = $15.0, 9.0, 2.8 \text{ Hz}, 2\alpha\text{-H}$ , 2.94 (ddd, 1 H, J = 15.0, 6.0, 2.9Hz,  $2\beta$ -H), 4.28 (dd, 1 H, J = 8.8, 5.5 Hz, 4-H), 4.82 (dq, 1H, J = 8.8, 6.2 Hz, 5-H), 5.10 (ddd, 1 H, J = 9.0, 5.5, 2.9)Hz, 3-H), 6.72 (dd, 1 H, J = 6.0, 2.8 Hz, 1-H), 7.71-7.84 (m, 4 H, phth). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 17.88 (C-6), 20.68 (OAc), 21.12 (OAc), 36.97 (C-2), 49.94 (C-3), 67.78 (C-5), 82.79 (C-4), 98.53 (C-1), 123.10 (C'-5), 131.29 (C'-3a), 134.12 (C'-4), 167.79 (C'-2), 169.54 (OAc), 169.88 (OAc). FAB MS m/z [DMSO, glycerol, NaCl] (%): 384 ( $M + Na^+$ , 40), 302 ( $M + H^+$ , 22). Anal. ( $C_{18}H_{19}NO_7$ ): C, H, N.

1-(5-O-Acetyl-3-phthalimido-2,3,6-trideoxy-α-L-ribo-hexofuranosyl)thymine (8) and 1-(5-O-acetyl-3-phthalimido-2,3,6trideoxy-\(\beta\)-L-ribo-hexofuranosyl)thymine (9). A mixture of silylated thymine 7 (676 mg, 2.50 mmol), 1,5-di-O-acetyl-2,3,6-trideoxy-3-phthalimido-β-L-ribo-hexofuranose 5 (735) mg, 2.03 mmol) dissolved in dry acetonitrile (20 ml) was cooled to -15 °C. Trimethylsilyl trifluoromethanesulfonate (1 ml) was added dropwise and the reaction was followed by analytical silica TLC with methanol-dichloromethane (10:90) as the eluent. After 30 min, the reaction mixture was diluted with dichloromethane (100 ml) and quenched with a saturated solution of sodium hydrogencarbonate (50 ml). After 10 min the organic phase was washed successively with a saturated solution of sodium hydrogencarbonate (2×50 ml) and water (50 ml) and dried over anhydrous magnesium sulfate. Evaporation of the solvent gave a white foam (695 mg) which was purified by flash chromatography (Merck silica 230-400 mesh, 2×30 cm, dichloromethanemethanol 95:5) to give a pure anomeric mixture of 8 and 9  $(\alpha:\beta \text{ ratio} = 1:1, 650 \text{ mg}, 75\%)$ . Compounds 8 and 9 were separated on HPLC (Waters Delta Pak C-18, 300 Å, 15 μ, 57×300 mm, ethanol-water 32:68) to give 200 mg of analytically pure  $\alpha$ -anomer 8 ( $t_R = 38 \text{ min}$ ) and 176 mg of analytically pure  $\beta$ -anomer 9 ( $t_R = 30 \text{ min}$ ).

α-Anomer 8: m.p. 240–241 °C. ¹H NMR (CDCl<sub>3</sub>): δ 1.25 (d, 3 H, J = 6.4 Hz, 6′-H), 2.01 (s, 3 H, CH<sub>3</sub>), 2.06 (s, 3 H, OAc), 2.73 (dd, 2 H, J = 9.6, 7.5 Hz, 2′α-H, 2′β-H), 4.63 (dd, 2 H, J = 7.3, 5.3 Hz, 4′-H), 4.95–5.06 (m, 2 H, 3′-H, 5′-H), 6.43 (t, 1 H, J = 7.5 Hz, 1′-H), 7.78 (s, 6-H), 7.77–7.92 (m, 4 H, phth), 8.99 (br s, 1 H, NH). ¹³C NMR (CDCl<sub>3</sub>): δ 12.68 (CH<sub>3</sub>), 15.61 (C′-6), 21.03 (OAc), 34.21 (C′-2), 49.96 (C′-3), 70.96 (C′-5), 80.84 (C′-4), 84.10 (C′-1), 111.85 (C-5), 123.55 (C″-4), 131.36 (C″-3a), 134.51 (C″-5), 135.18 (C-6), 150.36 (C-2), 163.53 (C-4), 167.47 (C″-2), 169.98 (OAc). MS: m/z (%): 427 (M<sup>+</sup>, 1), 302 (64), 148 (15), 95 (100). Anal. (C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>7</sub>): C, H, N.

β-Anomer 9: m.p. 271–272 °C. ¹H NMR (CDCl<sub>3</sub>): δ 1.29 (d, 3 H, J = 6.4 Hz, 6′-H), 1.96 (s, 3 H, CH<sub>3</sub>), 2.03 (s, 3 H, OAc), 2.30 (ddd, 1 H, J = 14.1, 11.0, 6.9 Hz, 2′β-H), 2.80 (ddd, 1 H, J = 14.1,6.9, 4.8 Hz, 2′α-H), 4.32 (t, 1 H, J = 5.7 Hz, 4′-H), 4.98 (ddd, 1 H, J = 11.0, 5.7, 4.8 Hz, 3′-H), 5.13 (dq, 1 H, J = 6.4, 5.7 Hz, 5′-H), 6.64 (t, 1 H, J = 6.9 Hz, 1′-H), 7.19 (s, 1 H, 6-H), 7.76–7.91 (m, 4 H, phth), 8.91 (br s, 1 H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 12.49 (CH<sub>3</sub>), 16.31 (C′-6), 21.00 (OAc), 35.79 (C′-2), 48.84 (C′-3), 70.56 (C′-5), 82.14 (C′-4), 85.18 (C′-1), 111.21 (C-5), 123.49 (C″-4), 131.34 (C″-3), 134.37 (C″-5), 134.91 (C-6), 149.86 (C-2), 163.36 (C-4), 167.31 (C″-2), 169.86 (OAc). MS: m/z (%): 427 (M<sup>+</sup>, 1), 302 (65), 148 (14), 95 (100). Anal. (C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>7</sub>): C, H, N.

1-(5-O-Acetyl-3-phthalimido-2,3,6-trideoxy-α-L-arabinohexofuranosyl)thymine (10). A mixture of silylated thymine 7 (1.15 g, 4.25 mmol) and 1,5-di-O-acetyl-2,3,6-trideoxy-3-phthalimido-α-L-arabino-hexofuranose 6 (1.50 g, 4.15 mmol) dissolved in dry acetonitrile (50 ml) was cooled to -35°C. Trimethylsilyl trifluoromethanesulfonate (1.5 ml) was added dropwise. After 15 min analytical silica TLC with dichloromethane-methanol (9:1) as the eluent showed the complete absence of compound 6. The reaction mixture was diluted with dichloromethane (100 ml) and quenched with a saturated solution of sodium hydrogenearbonate (50 ml). After 10 min, the organic phase was washed successively with a saturated solution of sodium hydrogencarbonate (2×50 ml) and water (50 ml). After being dried over anhydrous magnesium sulfate, the organic solution was concentrated to a white solid at reduced pressure. Yield 1.05 g (59%). Recrystallization from 96% ethanol gave analytically pure 10. Yield 0.95 g (54 %), m. p. 218-220 °C. <sup>1</sup>H NMR (DMSO- $d_6$ ):  $\delta$  1.19 (d, 3 H, J = 5.0 Hz, 6'-H), 1.76 (s, 3 H, CH<sub>3</sub>), 1.84 (s, 3 H, OAc), 2.70 (dt, 1 H, J =14.4, 7.0 Hz,  $2'\alpha$ -H), 2.85 (dd, 1 H, J = 14.4, 7.0 Hz,  $2'\beta$ -H), 4.63–4.65 (m, 2 H, 4'-H, 5'-H), 5.13–5.17 (m, 1 H, 3'-H), 6.64 (t, 1 H, J = 7.0 Hz, 1'-H), 7.70 (s, 1 H, 6-H), 7.88 (s, 4 H, phth).  ${}^{13}$ C NMR (DMSO- $d_6$ ):  $\delta$  12.03 (CH<sub>3</sub>), 17.88 (C'-6), 20.39 (OAc), 35.82 (C'-2), 50.72 (C'-3), 67.52 (C'-5), 83.58 (C'-4), 86.68 (C'-1), 109.66 (C-5), 122.92 (C"-4), 131.15 (C"-3a), 134.52 (C"-5), 137.04 (C-6), 150.54 (C-2), 163.72 (C-4), 167.80 (C"-2), 168.99 (OAc). Anal.  $(C_{21}H_{21}N_3O_7)$ : C, H, N.

General procedure for preparation of 11, 12 and 13. Compound 8, 9 or 10 (0.3 mmol) was dissolved in 33 % methylamine in absolute ethanol (20 ml). The solution was stirred overnight at 20 °C. Analytical silica TLC with methanol as the eluent showed the product as the spot of lowest  $R_{\rm f}$ . The solvent was evaporated off at reduced presure and the unprotected amino nucleoside was purified by flash chromatography (Merck silica, 230–400 mesh, 2×30 cm, methanol).

1-(3-Amino-2,3,6-trideoxy-α-L-ribo-hexofuranosyl)thymine (11). Yield 64 mg (83%). Hygroscopic oil. <sup>1</sup>H NMR

(DMSO- $d_6$ ): δ 1.11 (d, 3 H, J = 6.4 Hz, 6'-H), 1.78 (s, 3 H, CH<sub>3</sub>), 1.93 (ddd, 1 H, J = 11.3, 6.5, 4.9 Hz, 2'α-H), 2.07 (dt, 1 H, J = 11.3, 6.5 Hz, 2'β-H), 3.35 (t, 1 H, J = 4.5 Hz, 4'-H), 3.52–3.58 (m, 1 H, 3'-H), 3.78 (qd, 1 H, J = 6.4, 4.5 Hz, 5'-H), 6.15 (t, 1 H, J = 6.5 Hz, 1'-H), 7.67 (s, 1 H, 6-H).  $^{13}$ C NMR (DMSO- $d_6$ ): δ 12.18 (CH<sub>3</sub>), 20.09 (C'-6), 40.24 (C'-2), 51.20 (C'-3), 67.22 (C'-5), 83.32 (C'-1), 90.42 (C'-4), 109.29 (C-5), 136.29 (C-6), 150.42 (C-2), 163.70 (C-4). MS: m/z (%): 255 (M<sup>+</sup>, 5), 153 (8), 130 (100), 129 (25), 112 (12), 110 (10).  $C_{11}H_{17}N_3O_4$ : Calc. 255.12190. Found 255.12187. Anal. ( $C_{11}H_{17}N_3\cdot\frac{1}{4}H_2O$ ): C, H.

1-(3-Amino-2,3,6-trideoxy-β-L-ribo-hexofuranosyl)thymine (12). Yield 65 mg (85%), m.p. 76–78°C. <sup>1</sup>H NMR (DMSO- $d_6$ ): δ 1.07 (d, 3 H, J = 6.1 Hz, 6'-H), 1.71–1.80 (m, 1 H, 2'β-H), 1.80 (s, 1 H, CH<sub>3</sub>), 2.43–2.55 (m, 1 H, 2α-H), 3.43–3.69 (m, 3 H, 3'-H, 4'-H, 5'-H), 6.09 (t, 1 H, J = 6.0 Hz, 1'-H), 7.98 (s, 1 H, 6-H). <sup>13</sup>C NMR (DMSO- $d_6$ ): δ 12.21 (CH<sub>3</sub>), 19.61 (C'-6), 40.35 (C'-2), 52.10 (C'-3), 67.52 (C'-5), 84.50 (C'-1), 90.92 (C'-4), 108.88 (C-5), 137.24 (C-6), 150.51 (C-2), 163.81 (C-4). MS: m/z (%): 255 ( $M^+$ , 4), 153 (14), 130 (100), 129 (37), 126 (11), 112 (13), 110 (14). C<sub>11</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>: Calc. 255.12190. Found 255.12187. Anal. (C<sub>11</sub>H<sub>17</sub>N<sub>3</sub>· $\frac{1}{2}$ H<sub>2</sub>O): C, H.

*1-(3-Amino-2,3,6-trideoxy*-α-L-arabino-*hexofuranosyl)thymine* (13). Yield 60 mg (78%). Hygroscopic, m.p. 178–180°C. <sup>1</sup>H NMR (DMSO- $d_6$ ): δ 1.15 (d, 3 H, J = 5.7 Hz, 6′-H), 1.81 (s, 3 H, CH<sub>3</sub>), 2.04–2.20 (m, 2 H, 2′α-H, 2β-H), 3.67–3.87 (m, 3 H, 3′-H, 4′-H, 5′-H), 6.22 (t, 1 H, J = 6.7 Hz, 1′-H), 7.50 (s, 1 H, 6-H). <sup>13</sup>C NMR (DMSO- $d_6$ ): δ 12.02 (C′-6), 21.32 (CH<sub>3</sub>), 40.03 (C′-2), 51.96 (C′-3), 64.38 (C′-5), 84.61 (C′-1), 87.36 (C′-4), 109.55 (C-5), 136.15 (C-6), 150.37 (C-2), 163.71 (C-4). FAB MS (H<sub>2</sub>O, glycerol): 256 (M + H<sup>+</sup>, 100). Anal. (C<sub>11</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>, H<sub>2</sub>O): C, H, N.

### References

- Lown, J. W. Bioactive Reviews, Elsevier, Amsterdam, The Netherlands 1988, Vol. 6.
- Pelyvás, I. F., Monneret, C. and Herczegh, P. Synthetic Aspects of Aminodeoxy Sugars of Antibiotics, Springer-Verlag, Berlin, Germany 1988.
- Hauser, F. M. and Ellenberger, S. R. Chem. Rev. 86 (1986)
- Lin, T., Gao, Y. and Mancini, W. R. J. Med. Chem. 26 (1983) 1691.
- 5. Lin, T.-S. and Mancini, W. R. J. Med. Chem. 26 (1983) 544.
- 6. Lin, T.-S. and Prusoff, W. H. J. med. Chem. 21 (1978) 109.
- Lin, T.-S. and Prusoff, W. H. US Pat. 4, 604, 382 (1986), Chem. Abstr. 105 (1986) 173004u.
- 8. Krenitsky, T. A., Freemen, G. A., Shaver, S. R., Beacham, L. M., III, Hurlbert, S., Cohn, N. K., Elwell, L. P. and Selway, J. W. T. J. Med Chem. 26 (1983) 891.
- 9. Busson, R., Colla, L., Vanderhaeghe, H. and DeClercq, E. Nucl. Acid Res. 9 (1981) 49.
- Lin, T.-S., Chen, M. S., McLaren, C., Gao, Y.-S., Ghazzouli,
   I. and Prusoff, W. H. J. Med. Chem. 30 (1987) 440.

- Cheng, Y.-C., Dutschmann, G. E., Bastow, K. F., Sarngadharan, M. G. and Ting, R. Y. C. J. Biol. Chem. 262 (1987) 2187.
- De Clercq, E., Van Aerschot, A., Herdewijn, P., Baba, M., Pauwels, R. and Balkzarini, J. Nucleosides Nucleotides 8 (1989) 659.
- 13. Motawia, M. S., Wengel, J., Abdel-Megied, A. E.-S. and Pedersen, E. B. Synthesis (1989) 384.
- 14. Wengel, J., Lau, J. and Pedersen, E. B. Synthesis (1989) 829.
- 15. Lau, J., Pedersen, E. B. and Jensen, L. V. Arch. Pharm. (Weinheim) 324 (1991) 83.
- Gonzales, F., Lesage, S. and Perlin, A. S. Carbohydr. Res. 42 (1975) 267.
- White, J. D., Nolen, E. G. and Miller, C. H. J. Org. Chem. 51 (1986) 1150.
- 18. Vorbrüggen, H., Krolikiewicz, K. and Bennua, B. Chem. Ber. 114 (1981) 1234.
- 19. Vorbrüggen, H. and Höfle, G. Chem. Ber. 114 (1981) 1256.
- Petersen, H., Motawia, M. S., Andreasen, E. S., Jacobsen, J. P. and Pedersen, E. B. Chem. Scr. 28 (1988) 341.

Received November 19, 1990.